Nine studies included patients before starting any oncologic treatments, such as adjuvant or neo-adjuvant therapy [30,31,32,33,34,37,38,39,42], one enrolled BC patients undergoing radiotherapy [41], one study included women during aromatase inhibitors (AIs) treatment [35]; whilst three studies recruited women after completing antineoplastic treatments [18,36,43]. The gene discussed is CYP19A1; the disease is breast cancer.